Researchers and pharmaceutical developers gathered at ObesityWeek 2026 in the Washington, D.C., area this November to address two pressing questions in metabolic health: how next-generation obesity medications perform in clinical trials, and what happens when patients stop taking current injectable treatments. On November 14, Eli Lilly and Company announced trial results spanning Zepbound, Foundayo, and its investigational therapies EloraTZP and retatrutide during the annual meeting, which runs through November 17. At the same conference, researchers from the Cleveland Clinic presented a study of more than 20,000 patients showing that bariatric surgery and switching medications produce significantly better two-year weight loss than stopping therapy altogether.

Together, the presentations highlight a rapidly expanding pipeline of pharmacological treatments alongside growing real-world evidence that obesity requires continuous, long-term care planning.

Eli Lilly's Next-Generation Pipeline and Adolescent Data

In its conference disclosures, Eli Lilly highlighted Phase 2 trial data for EloraTZP, an investigational combination therapy pairing eloralintide with tirzepatide. Among adults living with overweight or obesity and type 2 diabetes, participants receiving EloraTZP achieved an average weight reduction of up to 23.3%, or 54.1 pounds, at 48 weeks from an average baseline weight of 232.4 pounds.

According to Reuters, the company also reported blood sugar (A1C) reductions of up to 2.9%, with up to 77% of treated participants reaching normal blood sugar levels and up to 60% no longer meeting body mass index (BMI) criteria for obesity.

Lilly also shared findings from its Phase 3 SURMOUNT-ADOLESCENTS study, which evaluated Zepbound (tirzepatide) in adolescents aged 12 to under 18 with obesity. As reported by Fidelity, adolescents treated with Zepbound experienced an average BMI reduction of 21.4% at 72 weeks, and more than half of the participants no longer met the BMI criteria for obesity. The trial assessments also noted improvements in weight-related quality-of-life measures, specifically regarding physical comfort and body esteem.

Beyond body weight and blood sugar metrics, Lilly's presentations included secondary and exploratory outcomes across its broader portfolio. According to Investing.com, conference materials for retatrutide included reported reductions in sleep-apnea breathing disruptions and knee-osteoarthritis pain.

Additionally, exit interviews with participants taking eloralintide indicated that 74% reported fewer food cravings and 52% experienced reduced "food noise," a term used to describe persistent, intrusive thoughts about eating.

Medical journalists and independent analysts emphasize caution when interpreting early conference numbers. While Lilly's press release and Reuters describe the 23.3% weight loss and 2.9% A1C reduction for EloraTZP as "up to" average results across specific dosing cohorts, Reuters noted that the company had released selected findings and had not yet published the full trial datasets. Without complete peer-reviewed data detailing adverse events, discontinuation rates, and outcomes across all dosing arms, these figures represent preliminary disclosures rather than definitive proof that every patient will experience similar benefits.

Comparing Strategies After Stopping Semaglutide or Tirzepatide

While pharmaceutical companies test newer compounds, clinicians are managing the practical realities of existing injectable therapies like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).

According to the 2026 Gallup National Health and Well-Being Index cited by the Cleveland Clinic, the share of U.S. adults currently taking GLP-1 medications for weight loss rose to 11% in 2026, up from 3% in 2024, with 15% of adults reporting having used the drugs at some point. Despite this rapid uptake, high out-of-pocket costs, insurance coverage restrictions, and gastrointestinal side effects frequently lead patients to stop treatment.

To evaluate what happens after patients alter or halt their initial regimen, Cleveland Clinic researcher Hamlet Gasoyan, Ph.D., and colleagues analyzed electronic health records from 20,486 patients who used injectable semaglutide or tirzepatide for at least three months between 2021 and 2023.

The study, published in eClinicalMedicine and presented on November 15 at ObesityWeek 2026 in National Harbor, Maryland, compared five distinct pathways over a two-year follow-up period: remaining on the initial medication, switching between semaglutide and tirzepatide, transitioning to an alternative obesity medication, undergoing bariatric surgery, or stopping pharmacological and surgical obesity treatment entirely.

Across all five pathways, bariatric surgery yielded the largest sustained weight reduction at the two-year mark. However, exact figures varied slightly across medical reporting depending on the specific statistical analysis referenced. According to the Cleveland Clinic's official summary, patients who underwent bariatric surgery lost an average of 28% of their body weight at two years. Meanwhile, Medscape reported a 28.2% average weight reduction in its coverage of the per-protocol analysis, while Healio reported an average weight loss of 26.6% after surgery.

Among non-surgical pathways, patients who switched between semaglutide and tirzepatide achieved an average weight loss of 16% at two years.

Those who stayed on their initial GLP-1 medication maintained an average weight reduction of nearly 11%, and patients who transitioned to a different class of obesity medication lost about 8%. In contrast, individuals who discontinued their injectable therapy without starting another medication or undergoing surgery retained only about 4% weight loss at two years and showed the smallest improvements in blood pressure and blood sugar control.

Subgroup data reported by Medscape offered closer insight into medication switching: patients who started on semaglutide and switched to tirzepatide lost an average of 6.6 pounds (3.0 kilograms) more than those who stayed on semaglutide. Conversely, patients who remained on tirzepatide achieved 10 pounds (4.5 kilograms) greater weight loss than those who switched from tirzepatide to semaglutide.

What These Findings Mean for Patients and Clinicians

The Cleveland Clinic investigators noted that stopping an injectable medication does not have to mean the end of obesity management. "When a patient stops a GLP-1 medication, the most important question is what comes next," study co-author Ali Aminian, M.D., director of Cleveland Clinic's Bariatric and Metabolic Institute, stated in the clinic's release.

"In our study, patients who stopped all treatment had the least weight loss and the smallest metabolic benefits, while those who moved on to another effective therapy, particularly bariatric surgery, did considerably better."

Because the Cleveland Clinic study is a real-world observational analysis of electronic health records rather than a randomized controlled trial, the patient groups may have differed at baseline in ways that influenced their outcomes. An observational correlation does not guarantee that switching medications or electing surgery will produce identical results for every person.

Which Lilly findings are fully reported, and which are preliminary?

The data presented by Eli Lilly for EloraTZP, Zepbound in adolescents, retatrutide, and eloralintide represent selected conference disclosures shared at ObesityWeek 2026. As Reuters noted, full trial results and complete safety breakdowns had not yet been released at the time of the announcement.

Why do reports give different weight-loss estimates for bariatric surgery?

Different medical news outlets cited distinct statistical breakdowns from the Cleveland Clinic study. While the Cleveland Clinic's main summary reported an average two-year weight loss of 28% for bariatric surgery, Medscape cited a per-protocol analysis figure of 28.2%, and Healio reported 26.6%.

What should guide a maintenance plan if a patient needs to stop a GLP-1 drug?

Patients facing insurance barriers, cost issues, or side effects should consult their healthcare provider before stopping treatment. As Dr. Gasoyan noted, the observational findings are designed to support individualized discussions between patients and clinicians regarding alternative medications or surgical options to prevent weight regain and maintain metabolic health.

Sources